drug
apomorphine hydrochloride
Marketedupdated 3mo agoby TruPharma LLC
Approvedcommunity read0 votes
indications
investigational
Parkinson's Disease
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 3, 2028
~1.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (60)
- Apr 19, 2036method-of-use (U-2825)US 10449146
- Apr 19, 2036method-of-use (U-2825)US 10449146
- Apr 19, 2036method-of-use (U-2825)US 10449146
- Apr 19, 2036method-of-use (U-2825)US 10449146
- Apr 19, 2036method-of-use (U-2825)US 10449146
- Apr 19, 2036method-of-use (U-2825)US 10959943
- Apr 19, 2036method-of-use (U-2825)US 10959943
- Apr 19, 2036method-of-use (U-2825)US 10959943
- Apr 19, 2036method-of-use (U-2825)US 10959943
- Apr 19, 2036method-of-use (U-2825)US 10959943
- Dec 16, 2031formulationUS 11419769
- Dec 16, 2031formulationUS 11419769
- Dec 16, 2031formulationUS 11419769
- Dec 16, 2031formulationUS 11419769
- Dec 16, 2031formulationUS 11419769
- Dec 16, 2031formulationUS 8414922
- Dec 16, 2031formulationUS 8414922
- Dec 16, 2031formulationUS 8414922
- Dec 16, 2031formulationUS 8414922
- Dec 16, 2031formulationUS 8414922
- Dec 16, 2031formulationUS 8846074
- Dec 16, 2031formulationUS 8846074
- Dec 16, 2031formulationUS 8846074
- Dec 16, 2031formulationUS 8846074
- Dec 16, 2031formulationUS 8846074
- Jun 11, 2030formulationUS 104207633.8y
- Jun 11, 2030formulationUS 104207633.8y
- Jun 11, 2030formulationUS 104207633.8y
- Jun 11, 2030formulationUS 104207633.8y
- Jun 11, 2030formulationUS 104207633.8y
- Jun 11, 2030formulationUS 90444753.8y
- Jun 11, 2030formulationUS 90444753.8y
- Jun 11, 2030formulationUS 90444753.8y
- Jun 11, 2030formulationUS 90444753.8y
- Jun 11, 2030formulationUS 90444753.8y
- Jun 11, 2030formulationUS 92832193.8y
- Jun 11, 2030formulationUS 92832193.8y
- Jun 11, 2030formulationUS 92832193.8y
- Jun 11, 2030formulationUS 92832193.8y
- Jun 11, 2030formulationUS 92832193.8y
- Jun 11, 2030method-of-use (U-2825)US 93269813.8y
- Jun 11, 2030method-of-use (U-2825)US 93269813.8y
- Jun 11, 2030method-of-use (U-2825)US 93269813.8y
- Jun 11, 2030method-of-use (U-2825)US 93269813.8y
- Jun 11, 2030method-of-use (U-2825)US 93269813.8y
- Jun 11, 2030formulationUS 96690193.8y
- Jun 11, 2030formulationUS 96690193.8y
- Jun 11, 2030formulationUS 96690193.8y
- Jun 11, 2030formulationUS 96690193.8y
- Jun 11, 2030formulationUS 96690193.8y
- Jun 11, 2030method-of-use (U-2825)US 96690213.8y
- Jun 11, 2030method-of-use (U-2825)US 96690213.8y
- Jun 11, 2030method-of-use (U-2825)US 96690213.8y
- Jun 11, 2030method-of-use (U-2825)US 96690213.8y
- Jun 11, 2030method-of-use (U-2825)US 96690213.8y
- Aug 7, 2029formulationUS 108210743.0y
- Aug 7, 2029formulationUS 108210743.0y
- Aug 7, 2029formulationUS 108210743.0y
- Aug 7, 2029formulationUS 108210743.0y
- Aug 7, 2029formulationUS 108210743.0y
FDA exclusivities (1)
- Feb 3, 2028NPNP1.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that